MIT professor and biotech entrepreneur Robert Langer and colleagues have created a synthetic version of the natural high-density lipoprotein (HDL)--or "good cholesterol"--for use in drug delivery to treat cardiovascular diseases such as atherosclerosis. The team used microfluidics to construct the µHDLs, which are easy-to-manufacture versions of the natural nanoparticle, according to the American Chemical Society. The study appeared in the journal ACS Nano. The work drew funding from NIH, the National Cancer Institute, the Prostate Cancer Foundation, the American Heart Association and the National Heart, Lung, and Blood Institute. More | Abstract